Comparing the current results to its competitors, Stoke Therapeutics Inc reported Revenue decrease in the 1 quarter 2026 year on year by -96.07 %, despite the revenue increase by the most of its competitors of 0.12 %, recorded in the same quarter.
Stoke Therapeutics Inc , slower than the average decrease reported by the company's competitors of -9.99 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -9.99 %
December 7, 2024
Stoke Therapeutics, Inc. a pioneering biotechnology company listed on Nasdaq under the symbol STOK, continues to make significant strides in the battle against Dravet syndrome a severe and often debilitating form of epilepsy. Employing its proprietary RNA medicine approach, Stoke Therapeutics focuses on harnessing the body’s intrinsic potential to restore protein expression. The latest data releases pertaining to their lead candidate, zorevunersen, underscore the potential of this therapeutic to act as a transformative, disease-modifying agent for individuals suffering from Dravet syndrome. Recent Open-Label Extension (OLE) Study Findings In a promising breakthrough, Stoke Therapeutics has shared new data ...
Wave Life Sciences Ltd is a biotechnology company focused on developing and commercializing nucleic acid therapies for rare genetic diseases. Their business model revolves around utilizing their proprietary chemistry platform to design and create custom-built, targeted medicines that can potentially address a wide range of genetic disorders. They aim to bring these therapies through preclinical and clinical development stages and ultimately deliver innovative treatments to patients in need.
Prothena Corporation Public Limited Company Share Performance
+2.03%
Over The Past 5 Days
Prothena Corporation Public Limited Company
Profile
Prothena Corporation is a biotechnology company that focuses on developing novel therapies for diseases related to protein misfolding and amyloidosis. Their business model includes leveraging their expertise in antibody and protein engineering to develop and commercialize drug candidates, collaborating with pharmaceutical partners to advance their therapeutic programs, and continuously conducting research and development to expand their pipeline of potential treatments. Their goal is to address unmet medical needs and provide innovative solutions for patients suffering from devastating diseases.
Pharming Group N.V. operates on a business model focused on the development, production, and commercialization of innovative therapeutic products for the treatment of rare diseases and unmet medical needs. The company primarily generates revenue by selling its approved products in various geographic markets and through strategic collaborations with pharmaceutical partners. Pharming Group N.V. also engages in research and development activities to expand its product pipeline and explore potential new treatments.
Ovid Therapeutics Inc's business model is focused on developing and commercializing innovative medicines for the treatment of rare neurological disorders.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company that focuses on the discovery and development of innovative drugs. Their business model revolves around identifying potential drug targets, conducting research and preclinical studies to validate these targets, and subsequently developing drugs through clinical trials for various therapeutic areas. They also collaborate with pharmaceutical companies for joint development and commercialization efforts, aiming to bring these drugs to market and improve patient outcomes.
Sources:
Stoke Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Stoke Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
